Zessly is a biosimilar medication primarily used in the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is designed to mimic the effects of the reference biologic, infliximab, by targeting and inhibiting the action of tumor necrosis factor-alpha (TNF-alpha), a substance in the body that can cause inflammation and lead to immune system disorders. By blocking the activity of TNF-alpha, Zessly helps to reduce inflammation, alleviate symptoms, and prevent disease progression. It is administered through intravenous infusion, and its use must be closely monitored by healthcare professionals to manage potential side effects and ensure its efficacy in individual treatment plans.